This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Valinomycin
DrugBank Accession Number
DB14057
Background

A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 1111.338
Monoisotopic: 1110.631160082
Chemical Formula
C54H90N6O18
Synonyms
  • Potassium ionophore I
  • Valinomicin
External IDs
  • ANTIBIOTIC N-329 B
  • BRN 0078657

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of bleeding can be increased when Valinomycin is combined with Acenocoumarol.
AstemizoleValinomycin may decrease the excretion rate of Astemizole which could result in a higher serum level.
AtazanavirValinomycin may decrease the excretion rate of Atazanavir which could result in a higher serum level.
AtenololValinomycin may decrease the excretion rate of Atenolol which could result in a higher serum level.
AtorvastatinValinomycin may decrease the excretion rate of Atorvastatin which could result in a higher serum level.
AtropineValinomycin may decrease the excretion rate of Atropine which could result in a higher serum level.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Valinomycin.
Belantamab mafodotinValinomycin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
BosentanThe risk or severity of liver damage can be increased when Bosentan is combined with Valinomycin.
BudesonideValinomycin may decrease the excretion rate of Budesonide which could result in a higher serum level.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
N561YS75MN
CAS number
2001-95-8
InChI Key
FCFNRCROJUBPLU-DNDCDFAISA-N
InChI
InChI=1S/C54H90N6O18/c1-22(2)34-49(67)73-31(19)43(61)55-38(26(9)10)53(71)77-41(29(15)16)47(65)59-36(24(5)6)51(69)75-33(21)45(63)57-39(27(11)12)54(72)78-42(30(17)18)48(66)60-35(23(3)4)50(68)74-32(20)44(62)56-37(25(7)8)52(70)76-40(28(13)14)46(64)58-34/h22-42H,1-21H3,(H,55,61)(H,56,62)(H,57,63)(H,58,64)(H,59,65)(H,60,66)/t31-,32-,33-,34+,35+,36+,37-,38-,39-,40+,41+,42+/m0/s1
IUPAC Name
(3S,6S,9R,12R,15S,18S,21R,24R,27S,30S,33R,36R)-6,18,30-trimethyl-3,9,12,15,21,24,27,33,36-nonakis(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexaazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone
SMILES
CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC(=O)[C@@H](NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC(=O)[C@@H](NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC1=O)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C

References

General References
  1. Pinkerton M, Steinrauf LK, Dawkins P: The molecular structure and some transport properties of valinomycin. Biochem Biophys Res Commun. 1969 May 22;35(4):512-8. [Article]
ChemSpider
21493802
BindingDB
50237619
ChEBI
28545
ChEMBL
CHEMBL223643
Wikipedia
Valinomycin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0108 mg/mLALOGPS
logP3.07ALOGPS
logP5.92ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)11.19ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area332.4 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity276.83 m3·mol-1ChemAxon
Polarizability116.72 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wilson A. (2016). New horizons in predictive drug metabolism and pharmacokinetics. The Royal Society of Chemistry. [ISBN:978-1-84973-828-6]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ueda K, Shimabuku AM, Konishi H, Fujii Y, Takebe S, Nishi K, Yoshida M, Beppu T, Komano T: Functional expression of human P-glycoprotein in Schizosaccharomyces pombe. FEBS Lett. 1993 Sep 20;330(3):279-82. doi: 10.1016/0014-5793(93)80888-2. [Article]
  2. Goda K, Krasznai Z, Gaspar R, Lankelma J, Westerhoff HV, Damjanovich S, Szabo G Jr: Reversal of multidrug resistance by valinomycin is overcome by CCCP. Biochem Biophys Res Commun. 1996 Feb 15;219(2):306-10. doi: 10.1006/bbrc.1996.0228. [Article]

Drug created at June 12, 2018 20:59 / Updated at June 12, 2020 16:53